

PCT

IAP10 Rec'd PCT/PTO 18 NOV 2005


PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) Zumbrunn et al. Examiner: Unassigned
Application No.: 10/550,778 Group Art Unit: Unassigned
Confirmation No: Unassigned Docket: 753-54 PCT/US
Filed: September 27, 2005 Dated: November 15, 2005
For: TEMPLATE-FIXED
PEPTIDOMIMETICS AS
MEDICAMENTS AGAINST
HIV AND CANCER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Commissioner for Patents, P.O. Box 1450,
Alexandria, Virginia 22313-1450
On November 15, 2005*

Signed: Barbara Thomas 

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

Attached hereto is Form PTO-1449 listing references which were cited in the International Search Report mailed March 18, 2004, for corresponding International Application No. PCT/EP2003/004641. A copy of this Search Report is enclosed herewith.

Since this Information Disclosure Statement is being submitted within three months of the filing date, no fee is believed to be necessary. If, however, a fee is necessary, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 08-2461.


If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' agent at the telephone number set forth below.

Respectfully submitted,



Gloria K. Szakiel
Registration No.: 45,149
Agent for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(973) 331-1700



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. 753-54 PCT/US	SERIAL NO. 10/550,778
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			APPLICANT Zumbrunn et al.	CONFIRMATION NO. Unassigned
			FILING DATE September 27, 2005	GROUP Unassigned

U.S. PATENT PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
		WO 01/16161	03/08/01	PCT				
		WO 02/070547	09/12/02	PCT				
		WO 03/054000	07/03/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Shankaramma et al.; Macrocyclic Hairpin Mimetics of the Cationic Antimicrobial Peptide Protegrin I: A New Family of Broad-Spectrum Antibiotics; ChemBioChem 2002, Vol. 3, pp 1126-1133
		Tamamura et al., Certification of the Critical Importance of L-3-(2-Naphthyl)alanine at Position 3 of a Specific CXCR4 Inhibitor, T140, Leads to an Exploratory Performance of Its Downsizing Study; Bioorganic & Medicinal Chemistry, Vol. 10 (2002), pp 1417-1426

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 753-54 PCT/US	SERIAL NO. 10/550,778
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Zumbrunn et al.	CONFIRMATION NO. Unassigned
(Use several sheets if necessary)		FILING DATE September 27, 2005	GROUP Unassigned

			Robinson; The Design, Synthesis and Conformation of Some New β -Hairpin Mimetics: Novel Reagents for Drug and Vaccine Discovery; <i>Synlett</i> , 2000; No. 4, pp 429-441
			Favre, et al.; Structural Mimicry of Canonical Conformations in Antibody Hypervariable Loops Using Cyclic Peptides Containing a Heterochiral Diproline Template; <i>J. Am. Chem. Soc.</i> , 1999, Vol. 121, pp.2679-2685
			Fujii et al.; Peptide-lead CXCR4 antagonists with high anti-HIV activity; <i>Current Opinion in Investigational Drugs</i> ; 2001 2(9); pp 1198-1202
			Tamamura et al.; Development of Specific CXCR4 Inhibitors Possessing High Selectivity Indexes as Well as Complete Stability in Serum Based on an Anti-HIV Peptide T140; <i>Bioorganic & Medicinal Chemistry Letters</i> 11 (2001) 1897-1902
			Tamarura et al.; Conformational Study of a Highly Specific CXCR4 Inhibitor, T140, Disclosing the Close Proximity of Its Intrinsic Pharmacophores Associated with Strong Anti-HIV Activity; <i>Bioorganic & Medicinal Chemistry Letters</i> 11 (2001) 359-362
			Jiang et al.; Combinatorial Biomimetic Chemistry: Parallel Synthesis of a Small Library of β -Hairpin Mimetics Based on Loop III from Human Platelet-Derived Growth Factor B; <i>Helvetica Chimica Acta</i> ; Vol. 83, (2000) pp 3097-3112
			Obrecht et al.; Novel Peptide Mimetic Building Blocks and Strategies for Efficient Lead Finding; <i>Advances in Medicinal Chemistry</i> ; 1999; Vol. 4, pp 1-68
			Hanessian et al., Design and Synthesis of Conformationally Constrained Amino Acids as Versatile Scaffolds and Peptide Mimetics; <i>Tetrahedron</i> , Vol. 53, No. 38; 1997; pp 12789-12854
			Sato et al., Solid phase synthesis of human growth hormone-releasing factor analogs containing a bicyclic β -turn dipeptide; <i>International Journal of Peptide & Protein Research</i> , October 1991; No. 4; pp 340-345

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.